MedTrace Logo

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

NCT01285089 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2014-01-30

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

Conditions

  • Acquired Bleeding Disorder
  • Acquired Haemophilia

Interventions

DRUG

activated recombinant human factor VII

Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • France

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01285089 on ClinicalTrials.gov